reports
Spexis Announces Changes to the Executive Committee
Spexis Announces Changes to the Executive Committee Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that Hernan Levett, currently Chief Financial Officer, has decided to pursue a new career opportunity outside the company. He will continue to support the company as a strategic advisor on financial transactions and will depart the company effective December 1, 2023. Martin Jakobovic, curren...
Spexis to host business update conference call on October 9, 2023
Spexis AG / Key word(s): Statement Spexis to host business update conference call on October 9, 2023 06.10.2023 / 07:30 CET/CEST Spexis to host business update conference call on October 9, 2023 Allschwil, Switzerland, October 6, 2023 Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT. Jeffrey D. Wager, M.D. (CEO & Chairman) will provide strategic business and financial updates. ...
Spexis to host business update conference call on October 9, 2023
Spexis to host business update conference call on October 9, 2023 ALLSCHWIL, Switzerland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT. Jeffrey D. Wager, M.D. (CEO & Chairman) will provide strategic business and financial updates. To access the conference call please use the following details: France: Germany: 0Italy: Switzerland United Kingdom United States In...
Spexis provides business update and announces financial results for th...
Spexis provides business update and announces financial results for the first half of 2023 Ad hoc announcement pursuant to Art. 53 LR Balixafortide, a potent CXCR4 inhibitor, to be evaluated for the treatment of pancreatic ductal adenocarcinoma (PDAC)Spexis closed capital commitments totaling USD $7.5 million supporting Phase 3 ColiFin® program in cystic fibrosis (CF) infectionsCOPILOT study expected to initiate in fourth quarter 2023Appointed Gonçalo Bernardes, PhD, as acting Head of Chemical BiologyAnnounced strong safety and pharmacokinetics results from first-in-human study wit...
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as actin...
Spexis AG / Key word(s): Statement Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology 28.09.2023 / 07:30 CET/CEST Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology Allschwil, Switzerland, September 28, 2023 Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology. Dr. Bernardes is a leader in the fields of chemistry and oncolog...
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as actin...
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology ALLSCHWIL, Switzerland, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology. Dr. Bernardes is a leader in the fields of chemistry and oncology and currently a Full Professor at the University of Cambridge. He also leads a satellite lab at the Insituto Medicina Molecular in Lisbon. Multiple discoveries m...
Spexis announces USD $2.5 million capital commitment to support the up...
Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced a capital commitment totaling USD $2.5 million with participation from SPRIM Global Investments (SGI) and institutional investors to fund the upcoming Phase 3 ColiFin® studies, beginning with the COPILOT study which is expected to initiate in...
Spexis announces engagement with Maxim Group LLC as M&A advisor to sup...
Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, June 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it has engaged Maxim Group LLC as a financial advisor to assist in the evaluation of strategic alternatives and fundraising opportunities. Spexis continues to seek additional funding, a strategic transaction or both to advance its ColiFin® Phase 3 program...
Spexis announces the publication of promising results for a novel clas...
Spexis AG / Key word(s): Scientific publication Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances 07.06.2023 / 07:30 CET/CEST Allschwil, Switzerland, June 6, 2023 Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carbapenem-resistant and colistin-resistant strains Novel antibiotics were dev...
Spexis announces the publication of promising results for a novel clas...
Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carbapenem-resistant and colistin-resistant strains Novel antibiotics were developed by Spexis in close collaboration with Professor Oliver Zerbe’s group at the University of Zurich with substantial funding by Innosuisse and CARB-X ALLSCHWIL, Switzerland, June 06, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceut...
Spexis provides business update and announces financial results for th...
Spexis provides business update and announces financial results for the full year 2022 Ad hoc announcement pursuant to Art. 53 LR USD 4.5 million capital commitment from SPRIM Global Investments to enable initiation of ColiFin® COPILOT study; first patient dosing expected in mid-2023Reported solid safety and pharmacokinetics results from first-in-human study of inhaled murepavadinAnnounced positive renal impairment clinical trial results with balixafortide ALLSCHWIL, Switzerland, May 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused o...
Spexis announces closing of capital commitment of USD 4.5 million from...
Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study Ad hoc announcement pursuant to Art. 53 LR Funding to enable immediate initiation of the COPILOT study, the first of two Phase 3 ColiFin® studies; first-patient-in expected in June 2023Commitment structured as a mix of secured debt and subordinated debt mandatorily converting into equity ALLSCHWIL, Switzerland, April 18, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and o...
Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical ...
Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin® Ad hoc announcement pursuant to Art. 53 LR SGI debt facility to provide Spexis up to half of the projected ColiFin® Phase 3 development costs, including those involving both COPILOT and COPASGI has invested in Spexis as part of the ColiFin® P3 clinical trial partnership financing; additional investments from other investors expected in the near futureSGI debt facility subject to a number of conditions, including negot...
Spexis reports solid safety and pharmacokinetics results from first-in...
Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound Ad hoc announcement pursuant to Art. 53 LR Inhaled murepavadin shown to be well tolerated at all dose levels Program derived from Spexis’ macrocycle platformData support moving forward to Phase 2 in cystic fibrosis and non-cystic fibrosis bronchiectasis lung infection ALLSCHWIL, Switzerland, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, toda...
Spexis gibt vielversprechende präklinische Daten für Balixafortide in ...
Spexis AG / Schlagwort(e): Research Update/Studienergebnisse Spexis gibt vielversprechende präklinische Daten für Balixafortide in Kombination mit bereits erhältlichen Therapien zur Behandlung von B-Zell-Lymphomen bekannt 13.12.2022 / 07:30 CET/CEST Allschwil, Schweiz, 13. Dezember 2022 Spexis gibt vielversprechende präklinische Daten für Balixafortide in Kombination mit bereits erhältlichen Therapien zur Behandlung von B-Zell-Lymphomen bekannt Balixafortide zeigt synergistische oder additive Effekte mit konventionellen oder zielgerichteten Therapien bei allen getest...
Spexis announces promising pre-clinical data with balixafortide in com...
Spexis AG / Key word(s): Research Update/Study results Spexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas 13.12.2022 / 07:30 CET/CEST Allschwil, Switzerland, December 13, 2022 Spexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas Balixafortide shown to have synergistic or additive effect with conventional or targeted therapies across all tested B-cell lymphomas Spexis AG (SIX: SPE...
Spexis announces promising pre-clinical data with balixafortide in com...
Spexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas Balixafortide shown to have synergistic or additive effect with conventional or targeted therapies across all tested B-cell lymphomas ALLSCHWIL, Switzerland, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced results from an in vitro study evaluating the effects of combining Spexis’ potent CXCR4 inhibitor balixafortide (BLX) with several co...
Spexis to present at BIO-Europe® 2022
Spexis AG / Key word(s): Conference Spexis to present at BIO-Europe® 2022 18.10.2022 / 07:30 CET/CEST Allschwil, Switzerland, October 18, 2022 Spexis to present at BIO-Europe® 2022 Spexis AG (SIX: SPEX) today announced that the company will present and participate in one-on-one meetings at , taking place October 24-26, 2022 in Leipzig, Germany, and virtually, November 2-4, 2022. Jeff Wager, CEO of Spexis, will provide an overview of the company and its pipeline. The in-person presentation will be on Tuesday, October 25th from 13:30 to 13:45 CEST in Multi-purpose Room 4....
Spexis announces positive renal impairment clinical trial results with...
Spexis announces positive renal impairment clinical trial results with balixafortide Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and well tolerated Safety findings support potential to use significantly higher doses of balixafortide than those previously investigatedAdditional observations indicate potential for stimulating prolonged stem cell mobilization, a potentially key advantage in implementing hematopoietic stem cell transplantation ALLSCHWIL, Switzerland, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-...
Spexis provides business update and announces financial results for th...
Spexis provides business update and announces financial results for the first half of 2022 Ad hoc announcement pursuant to Art. 53 LR Study start-up activities nearly complete for COPILOT, the first part of the Phase 3 ColiFin® program, including regulatory and ethics committee approvals of trial sites Enrollment of Phase 1 trial of inhaled murepavadin in healthy volunteers continues with top-line results expected by year-end 2022Analysis of balixafortide PK/safety clinical trial in renally impaired subjects completed; results expected to be announced this fall Good progress in earlier-sta...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.